| Joshua Baalwa, MD | |
|
619 19th St S, Birmingham, AL 35249-1967 | |
| (205) 934-4011 | |
| Not Available |
| Full Name | Joshua Baalwa |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 26 Years |
| Location | 619 19th St S, Birmingham, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720423270 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 46771 (Texas) | Secondary |
| 207ZP0101X | Pathology - Anatomic Pathology | 45503 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Medical Center East | Montgomery, AL | Hospital |
| Baptist Medical Center South | Montgomery, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Alabama Health Services Foundation, Pc | 1951213107 | 2344 |
News Archive
An international research team led by scientists at the University of Alabama at Birmingham has identified a potential target for therapeutics that might help slow the progression of Parkinson's disease.
Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Nature describing the discovery and validation of the role of the gene Sort1 in the development of cardiovascular disease, including myocardial infarction (MI). This work was done with collaborators at University of Pennsylvania (UPenn) School of Medicine, Massachusetts General Hospital (MGH), and the Broad Institute. The collaborative effort combined genome-wide association studies (GWAS) and RNAi technology to identify and validate novel genes as targets for new therapies for heart disease.
W. L. Gore & Associates today announced the European availability of the GORE VIABAHN Endoprosthesis on a lower profile delivery system. The announcement came during the Leipzig Interventional Course in Germany, where European interventionalists gathered to discuss new approaches in treating patients suffering from peripheral artery disease.
Scientists have identified metabolites in the blood that accurately predict whether a woman will develop type 2 diabetes after experiencing a transient form of illness during pregnancy.
Siemens Healthineers announced today the company is expanding its informatics capabilities for point-of-care testing with the acquisition of Conworx Technology GmbH, the Berlin-based developer of point-of-care device interfaces and data management solutions.
› Verified 3 days ago
| Entity Name | University Of Alabama Health Services Foundation, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093768723 PECOS PAC ID: 1951213107 Enrollment ID: O20031105000261 |
News Archive
An international research team led by scientists at the University of Alabama at Birmingham has identified a potential target for therapeutics that might help slow the progression of Parkinson's disease.
Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Nature describing the discovery and validation of the role of the gene Sort1 in the development of cardiovascular disease, including myocardial infarction (MI). This work was done with collaborators at University of Pennsylvania (UPenn) School of Medicine, Massachusetts General Hospital (MGH), and the Broad Institute. The collaborative effort combined genome-wide association studies (GWAS) and RNAi technology to identify and validate novel genes as targets for new therapies for heart disease.
W. L. Gore & Associates today announced the European availability of the GORE VIABAHN Endoprosthesis on a lower profile delivery system. The announcement came during the Leipzig Interventional Course in Germany, where European interventionalists gathered to discuss new approaches in treating patients suffering from peripheral artery disease.
Scientists have identified metabolites in the blood that accurately predict whether a woman will develop type 2 diabetes after experiencing a transient form of illness during pregnancy.
Siemens Healthineers announced today the company is expanding its informatics capabilities for point-of-care testing with the acquisition of Conworx Technology GmbH, the Berlin-based developer of point-of-care device interfaces and data management solutions.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joshua Baalwa, MD Po Box 55310, Birmingham, AL 35255-5310 Ph: () - | Joshua Baalwa, MD 619 19th St S, Birmingham, AL 35249-1967 Ph: (205) 934-4011 |
News Archive
An international research team led by scientists at the University of Alabama at Birmingham has identified a potential target for therapeutics that might help slow the progression of Parkinson's disease.
Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Nature describing the discovery and validation of the role of the gene Sort1 in the development of cardiovascular disease, including myocardial infarction (MI). This work was done with collaborators at University of Pennsylvania (UPenn) School of Medicine, Massachusetts General Hospital (MGH), and the Broad Institute. The collaborative effort combined genome-wide association studies (GWAS) and RNAi technology to identify and validate novel genes as targets for new therapies for heart disease.
W. L. Gore & Associates today announced the European availability of the GORE VIABAHN Endoprosthesis on a lower profile delivery system. The announcement came during the Leipzig Interventional Course in Germany, where European interventionalists gathered to discuss new approaches in treating patients suffering from peripheral artery disease.
Scientists have identified metabolites in the blood that accurately predict whether a woman will develop type 2 diabetes after experiencing a transient form of illness during pregnancy.
Siemens Healthineers announced today the company is expanding its informatics capabilities for point-of-care testing with the acquisition of Conworx Technology GmbH, the Berlin-based developer of point-of-care device interfaces and data management solutions.
› Verified 3 days ago
Dr. Kyle Charles Mills, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 3550 Independence Dr, Birmingham, AL 35209 Phone: 205-949-2800 Fax: 205-949-2801 | |
Leona Council, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 619 19th St S, Birmingham, AL 35249 Phone: 205-934-5038 | |
Dr. Alexander Wong, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 3550 Independence Dr, Birmingham, AL 35209 Phone: 205-949-2806 Fax: 205-949-2875 | |
Dr. David Ullman, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 625 19th St S, Birmingham, AL 35233 Phone: 205-934-4977 | |
Dr. Jonathan G Phillips, MD Pathology Medicare: Medicare Enrolled Practice Location: 924 Montclair Rd, Ste 200, Birmingham, AL 35213 Phone: 205-591-7999 Fax: 205-591-5051 | |
Thomas S Winokur, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 619 19th Street South, Birmingham, AL 35233 Phone: 205-934-6600 | |
Isam Eltoum, Pathology Medicare: Accepting Medicare Assignments Practice Location: 2000 6th Ave S, Birmingham, AL 35233 Phone: 205-934-9999 |